

# Julio Rosenstock

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1592563/publications.pdf>

Version: 2024-02-01

188  
papers

28,105  
citations

8159

76  
h-index

5519

163  
g-index

188  
all docs

188  
docs citations

188  
times ranked

12739  
citing authors

#	ARTICLE	IF	CITATIONS
1	Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2016, 375, 1834-1844.	13.9	3,898
2	The Treat-to-Target Trial: Randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. <i>Diabetes Care</i> , 2003, 26, 3080-3086.	4.3	1,430
3	Once-Weekly Semaglutide in Adults with Overweight or Obesity. <i>New England Journal of Medicine</i> , 2021, 384, 989-1002.	13.9	1,374
4	Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). <i>Lancet, The</i> , 2009, 374, 39-47.	6.3	1,324
5	Effects of Exenatide (Exendin-4) on Glycemic Control Over 30 Weeks in Patients With Type 2 Diabetes Treated With Metformin and a Sulfonylurea. <i>Diabetes Care</i> , 2005, 28, 1083-1091.	4.3	1,125
6	Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 69.	3.8	830
7	Euglycemic Diabetic Ketoacidosis: A Predictable, Detectable, and Preventable Safety Concern With SGLT2 Inhibitors. <i>Diabetes Care</i> , 2015, 38, 1638-1642.	4.3	513
8	Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: A 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. <i>Clinical Therapeutics</i> , 2006, 28, 1556-1568.	1.1	475
9	Use of Twice-Daily Exenatide in Basal Insulin-Treated Patients With Type 2 Diabetes. <i>Annals of Internal Medicine</i> , 2011, 154, 103.	2.0	460
10	Canagliflozin Compared With Sitagliptin for Patients With Type 2 Diabetes Who Do Not Have Adequate Glycemic Control With Metformin Plus Sulfonylurea. <i>Diabetes Care</i> , 2013, 36, 2508-2515.	4.3	429
11	Semaglutide 2-4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. <i>Lancet, The</i> , 2021, 397, 971-984.	6.3	429
12	Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 1155.	3.8	423
13	Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 1414.	3.8	413
14	Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. <i>Lancet, The</i> , 2021, 398, 143-155.	6.3	407
15	Dose-Ranging Effects of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as Add-On to Metformin in Subjects With Type 2 Diabetes. <i>Diabetes Care</i> , 2012, 35, 1232-1238.	4.3	372
16	Reduced Hypoglycemia Risk With Insulin Glargine: A meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes. <i>Diabetes Care</i> , 2005, 28, 950-955.	4.3	360
17	Effects of Dapagliflozin, an SGLT2 Inhibitor, on HbA1c, Body Weight, and Hypoglycemia Risk in Patients With Type 2 Diabetes Inadequately Controlled on Pioglitazone Monotherapy. <i>Diabetes Care</i> , 2012, 35, 1473-1478.	4.3	344
18	Cardiovascular and Renal Outcomes with Efglenatide in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2021, 385, 896-907.	13.9	339

#	ARTICLE	IF	CITATIONS
19	Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From a Diabetes Care Editors' Expert Forum. Diabetes Care, 2018, 41, 14-31.	4.3	338
20	Improved Glucose Control With Weight Loss, Lower Insulin Doses, and No Increased Hypoglycemia With Empagliflozin Added to Titrated Multiple Daily Injections of Insulin in Obese Inadequately Controlled Type 2 Diabetes. Diabetes Care, 2014, 37, 1815-1823.	4.3	311
21	Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet, The, 2012, 379, 1498-1507.	6.3	304
22	Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes. JAMA - Journal of the American Medical Association, 2017, 318, 1460.	3.8	301
23	Once-weekly abiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study. Lancet Diabetes and Endocrinology, the, 2014, 2, 289-297.	5.5	293
24	Comparison of Vildagliptin and Rosiglitazone Monotherapy in Patients With Type 2 Diabetes: A 24-week, double-blind, randomized trial. Diabetes Care, 2007, 30, 217-223.	4.3	269
25	Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled by Established Basal Insulin. Diabetes Care, 2013, 36, 2489-2496.	4.3	261
26	Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet, The, 2021, 398, 1811-1824.	6.3	257
27	Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes and Endocrinology, the, 2017, 5, 864-876.	5.5	244
28	Colesevelam HCl Improves Glycemic Control and Reduces LDL Cholesterol in Patients With Inadequately Controlled Type 2 Diabetes on Sulfonylurea-Based Therapy. Diabetes Care, 2008, 31, 1479-1484.	4.3	242
29	Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials. Diabetes Care, 2018, 41, 2560-2569.	4.3	239
30	Dual Add-on Therapy in Type 2 Diabetes Poorly Controlled With Metformin Monotherapy: A Randomized Double-Blind Trial of Saxagliptin Plus Dapagliflozin Addition Versus Single Addition of Saxagliptin or Dapagliflozin to Metformin. Diabetes Care, 2015, 38, 376-383.	4.3	234
31	Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea. JAMA - Journal of the American Medical Association, 2019, 321, 1466.	3.8	233
32	PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes. Diabetes Care, 2019, 42, 1724-1732.	4.3	227
33	Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled With Newly Initiated and Continuously Titrated Basal Insulin Glargine. Diabetes Care, 2013, 36, 2497-2503.	4.3	225
34	Efficacy and Safety of Lixisenatide Once Daily Versus Exenatide Twice Daily in Type 2 Diabetes Inadequately Controlled on Metformin. Diabetes Care, 2013, 36, 2945-2951.	4.3	225
35	Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial. Diabetes Care, 2019, 42, 2272-2281.	4.3	225
36	Contrasting Effects of Lixisenatide and Liraglutide on Postprandial Glycemic Control, Gastric Emptying, and Safety Parameters in Patients With Type 2 Diabetes on Optimized Insulin Glargine With or Without Metformin: A Randomized, Open-Label Trial. Diabetes Care, 2015, 38, 1263-1273.	4.3	216

#	ARTICLE	IF	CITATIONS
37	Triple Therapy in Type 2 Diabetes: Insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients. <i>Diabetes Care</i> , 2006, 29, 554-559.	4.3	215
38	Potential of Albiglutide, a Long-Acting GLP-1 Receptor Agonist, in Type 2 Diabetes. <i>Diabetes Care</i> , 2009, 32, 1880-1886.	4.3	209
39	Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial. <i>Diabetes Care</i> , 2016, 39, 1972-1980.	4.3	198
40	Design and baseline characteristics of the CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes (CAROLINA <sup>®</sup> ). <i>Diabetes and Vascular Disease Research</i> , 2015, 12, 164-174.	0.9	197
41	Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial. <i>Diabetes Care</i> , 2016, 39, 2026-2035.	4.3	197
42	Effects of Exenatide and Lifestyle Modification on Body Weight and Glucose Tolerance in Obese Subjects With and Without Pre-Diabetes. <i>Diabetes Care</i> , 2010, 33, 1173-1175.	4.3	195
43	Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes. <i>Diabetes Care</i> , 2015, 38, 1181-1188.	4.3	194
44	Exploring the Potential of the SGLT2 Inhibitor Dapagliflozin in Type 1 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Pilot Study. <i>Diabetes Care</i> , 2015, 38, 412-419.	4.3	191
45	Contributions of Basal and Postprandial Hyperglycemia Over a Wide Range of A1C Levels Before and After Treatment Intensification in Type 2 Diabetes. <i>Diabetes Care</i> , 2011, 34, 2508-2514.	4.3	190
46	Advancing Basal Insulin Replacement in Type 2 Diabetes Inadequately Controlled With Insulin Glargine Plus Oral Agents: A Comparison of Adding Albiglutide, a Weekly GLP-1 Receptor Agonist, Versus Thrice-Daily Prandial Insulin Lispro. <i>Diabetes Care</i> , 2014, 37, 2317-2325.	4.3	186
47	Advancing Insulin Therapy in Type 2 Diabetes Previously Treated With Glargine Plus Oral Agents. <i>Diabetes Care</i> , 2008, 31, 20-25.	4.3	184
48	Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes: The DEPICT-1 52-Week Study. <i>Diabetes Care</i> , 2018, 41, 2552-2559.	4.3	177
49	Repaglinide Versus Nateglinide Monotherapy: A randomized, multicenter study. <i>Diabetes Care</i> , 2004, 27, 1265-1270.	4.3	171
50	Sotagliflozin in Combination With Optimized Insulin Therapy in Adults With Type 1 Diabetes: The North American inTandem1 Study. <i>Diabetes Care</i> , 2018, 41, 1970-1980.	4.3	170
51	More Similarities Than Differences Testing Insulin Glargine 300 Units/mL Versus Insulin Degludec 100 Units/mL in Insulin-Naive Type 2 Diabetes: The Randomized Head-to-Head BRIGHT Trial. <i>Diabetes Care</i> , 2018, 41, 2147-2154.	4.3	159
52	Weight regain and cardiometabolic effects after withdrawal of semaglutide: The <sc>STEP</sc> 1 trial extension. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 1553-1564.	2.2	151
53	Effects of the Dipeptidyl Peptidase-IV Inhibitor Vildagliptin on Incretin Hormones, Islet Function, and Postprandial Glycemia in Subjects With Impaired Glucose Tolerance. <i>Diabetes Care</i> , 2008, 31, 30-35.	4.3	147
54	Inhaled Insulin Improves Glycemic Control When Substituted for or Added to Oral Combination Therapy in Type 2 Diabetes. <i>Annals of Internal Medicine</i> , 2005, 143, 549.	2.0	146

#	ARTICLE	IF	CITATIONS
55	Sequential Intensification of Metformin Treatment in Type 2 Diabetes With Liraglutide Followed by Randomized Addition of Basal Insulin Prompted by A1C Targets. <i>Diabetes Care</i> , 2012, 35, 1446-1454.	4.3	145
56	The potential role and rationale for treatment of heart failure with sodium-glucose cotransporter 2 inhibitors. <i>European Journal of Heart Failure</i> , 2017, 19, 1390-1400.	2.9	139
57	Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: Rationale for the active-comparator CAROLINA trial. <i>Diabetes and Vascular Disease Research</i> , 2013, 10, 289-301.	0.9	132
58	Once-Weekly Insulin for Type 2 Diabetes without Previous Insulin Treatment. <i>New England Journal of Medicine</i> , 2020, 383, 2107-2116.	13.9	131
59	Personalized Management of Hyperglycemia in Type 2 Diabetes: Reflections from a Diabetes Care Editors' Expert Forum. <i>Diabetes Care</i> , 2013, 36, 1779-1788.	4.3	130
60	Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA. <i>Circulation</i> , 2019, 139, 351-361.	1.6	126
61	Liraglutide Treatment Is Associated with a Low Frequency and Magnitude of Antibody Formation with No Apparent Impact on Glycemic Response or Increased Frequency of Adverse Events: Results from the Liraglutide Effect and Action in Diabetes (LEAD) Trials. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, 1695-1702.	1.8	125
62	Effects of Adding Linagliptin to Basal Insulin Regimen for Inadequately Controlled Type 2 Diabetes. <i>Diabetes Care</i> , 2013, 36, 3875-3881.	4.3	124
63	Patient Satisfaction and Glycemic Control After 1 Year With Inhaled Insulin (Exubera) in Patients With Type 1 or Type 2 Diabetes. <i>Diabetes Care</i> , 2004, 27, 1318-1323.	4.3	123
64	Prandial Options to Advance Basal Insulin Glargine Therapy: Testing Lixisenatide Plus Basal Insulin Versus Insulin Glulisine Either as Basal-Plus or Basal-Bolus in Type 2 Diabetes: The GetGoal Duo-2 Trial. <i>Diabetes Care</i> , 2016, 39, 1318-1328.	4.3	116
65	Update and Next Steps for Real-World Translation of Interventions for Type 2 Diabetes Prevention: Reflections From a Diabetes Care Editors' Expert Forum. <i>Diabetes Care</i> , 2016, 39, 1186-1201.	4.3	113
66	Management of Type 2 Diabetes in Treatment-Naive Elderly Patients: Benefits and risks of vildagliptin monotherapy. <i>Diabetes Care</i> , 2007, 30, 3017-3022.	4.3	112
67	Prandial inhaled insulin plus basal insulin glargine versus twice daily bipart insulin for type 2 diabetes: a multicentre randomised trial. <i>Lancet, The</i> , 2010, 375, 2244-2253.	6.3	111
68	Beneficial effects of once-daily lixisenatide on overall and postprandial glycemic levels without significant excess of hypoglycemia in Type 2 diabetes inadequately controlled on a sulphonylurea with or without metformin (GetGoal-S). <i>Journal of Diabetes and Its Complications</i> , 2014, 28, 386-392.	1.2	109
69	SERENADE: The Study Evaluating Rimonabant Efficacy in Drug-Naive Diabetic Patients. <i>Diabetes Care</i> , 2008, 31, 2169-2176.	4.3	108
70	Initial Combination Therapy With Canagliflozin Plus Metformin Versus Each Component as Monotherapy for Drug-Naive Type 2 Diabetes. <i>Diabetes Care</i> , 2016, 39, 353-362.	4.3	105
71	Initial Combination Therapy With Alogliptin and Pioglitazone in Drug-Naive Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2010, 33, 2406-2408.	4.3	98
72	Treatment satisfaction in type 2 diabetes: A comparison between an inhaled insulin regimen and a subcutaneous insulin regimen. <i>Clinical Therapeutics</i> , 2002, 24, 552-564.	1.1	95

#	ARTICLE	IF	CITATIONS
73	The Fate of Taspoglutide, a Weekly GLP-1 Receptor Agonist, Versus Twice-Daily Exenatide for Type 2 Diabetes. <i>Diabetes Care</i> , 2013, 36, 498-504.	4.3	93
74	Kidney Disease End Points in a Pooled Analysis of Individual Patient-Level Data From a Large Clinical Trials Program of the Dipeptidyl Peptidase 4 Inhibitor Linagliptin in Type 2 Diabetes. <i>American Journal of Kidney Diseases</i> , 2015, 66, 441-449.	2.1	91
75	Management of Type 2 Diabetes Mellitus in the Elderly. <i>Drugs and Aging</i> , 2001, 18, 31-44.	1.3	88
76	Coadministration of Canagliflozin and Phentermine for Weight Management in Overweight and Obese Individuals Without Diabetes: A Randomized Clinical Trial. <i>Diabetes Care</i> , 2017, 40, 632-639.	4.3	84
77	Initial Combination of Empagliflozin and Metformin in Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2016, 39, 1718-1728.	4.3	72
78	Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Lixisenatide and Insulin Glargine, Versus Insulin Glargine in Type 2 Diabetes Inadequately Controlled on Metformin Monotherapy: The LixiLan Proof-of-Concept Randomized Trial. <i>Diabetes Care</i> , 2016, 39, 1579-1586.	4.3	72
79	Continuous subcutaneous delivery of exenatide via ITCA 650 leads to sustained glycemic control and weight loss for 48 weeks in metformin-treated subjects with type 2 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2014, 28, 393-398.	1.2	71
80	Cardiovascular safety of linagliptin in type 2 diabetes: a comprehensive patient-level pooled analysis of prospectively adjudicated cardiovascular events. <i>Cardiovascular Diabetology</i> , 2015, 14, 57.	2.7	71
81	Rationale, design, and baseline characteristics of the Cardiovascular safety and Renal Microvascular outcome study with LINagliptin (CARMELINA <sup>®</sup> ): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk. <i>Cardiovascular Diabetology</i> , 2018, 17, 39.	2.7	70
82	Novel therapies with precision mechanisms for type 2 diabetes mellitus. <i>Nature Reviews Endocrinology</i> , 2021, 17, 364-377.	4.3	70
83	A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Topiramate Controlled Release in the Treatment of Obese Type 2 Diabetic Patients. <i>Diabetes Care</i> , 2007, 30, 1480-1486.	4.3	69
84	Greater Dose-Ranging Effects on A1C Levels Than on Glucosuria With LX4211, a Dual Inhibitor of SGLT1 and SGLT2, in Patients With Type 2 Diabetes on Metformin Monotherapy. <i>Diabetes Care</i> , 2015, 38, 431-438.	4.3	66
85	Glucagon-Like Peptide 1 Receptor Agonists and Heart Failure. <i>Circulation</i> , 2020, 142, 1205-1218.	1.6	63
86	Dipeptidyl peptidase-4 inhibitors and the management of type 2 diabetes mellitus. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2007, 14, 98-107.	1.2	62
87	Efpeglenatide and Clinical Outcomes With and Without Concomitant Sodium-Glucose Cotransporter-2 Inhibition Use in Type 2 Diabetes: Exploratory Analysis of the AMPLITUDE-O Trial. <i>Circulation</i> , 2022, 145, 565-574.	1.6	59
88	Beyond Metformin: Safety Considerations in the Decision-Making Process for Selecting a Second Medication for Type 2 Diabetes Management. <i>Diabetes Care</i> , 2014, 37, 2647-2659.	4.3	58
89	Switching to Once-Weekly Insulin Icodec Versus Once-Daily Insulin Glargine U100 in Type 2 Diabetes Inadequately Controlled on Daily Basal Insulin: A Phase 2 Randomized Controlled Trial. <i>Diabetes Care</i> , 2021, 44, 1586-1594.	4.3	56
90	Effect of exenatide QW or placebo, both added to titrated insulin glargine, in uncontrolled type 2 diabetes: The DURATION-7 randomized study. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 1602-1614.	2.2	54

#	ARTICLE	IF	CITATIONS
91	Effect of Linagliptin on Cognitive Performance in Patients With Type 2 Diabetes and Cardiorenal Comorbidities: The CARMELINA Randomized Trial. <i>Diabetes Care</i> , 2019, 42, 1930-1938.	4.3	52
92	Improved Time in Range and Glycemic Variability With Sotagliflozin in Combination With Insulin in Adults With Type 1 Diabetes: A Pooled Analysis of 24-Week Continuous Glucose Monitoring Data From the inTandem Program. <i>Diabetes Care</i> , 2019, 42, 919-930.	4.3	51
93	Composite Primary End Points in Cardiovascular Outcomes Trials Involving Type 2 Diabetes Patients: Should Unstable Angina Be Included in the Primary End Point?. <i>Diabetes Care</i> , 2017, 40, 1144-1151.	4.3	50
94	Switching to iGlarLixi Versus Continuing Daily or Weekly GLP-1 RA in Type 2 Diabetes Inadequately Controlled by GLP-1 RA and Oral Antihyperglycemic Therapy: The LixiLan-G Randomized Clinical Trial. <i>Diabetes Care</i> , 2019, 42, 2108-2116.	4.3	50
95	Impact of Liraglutide on Amylase, Lipase, and Acute Pancreatitis in Participants With Overweight/Obesity and Normoglycemia, Prediabetes, or Type 2 Diabetes: Secondary Analyses of Pooled Data From the SCALE Clinical Development Program. <i>Diabetes Care</i> , 2017, 40, 839-848.	4.3	49
96	Combination Therapy With Nateglinide and a Thiazolidinedione Improves Glycemic Control in Type 2 Diabetes. <i>Diabetes Care</i> , 2002, 25, 1529-1533.	4.3	48
97	Efficacy and Safety of Technosphere Inhaled Insulin Compared With Technosphere Powder Placebo in Insulin-Naive Type 2 Diabetes Suboptimally Controlled With Oral Agents. <i>Diabetes Care</i> , 2008, 31, 2177-2182.	4.3	48
98	Effects of Linagliptin on Cardiovascular and Kidney Outcomes in People With Normal and Reduced Kidney Function: Secondary Analysis of the CARMELINA Randomized Trial. <i>Diabetes Care</i> , 2020, 43, 1803-1812.	4.3	44
99	Randomized Trial of Continuous Subcutaneous Delivery of Exenatide by ITCA 650 Versus Twice-Daily Exenatide Injections in Metformin-Treated Type 2 Diabetes. <i>Diabetes Care</i> , 2013, 36, 2559-2565.	4.3	43
100	One-year sustained glycemic control and weight reduction in type 2 diabetes after addition of liraglutide to metformin followed by insulin detemir according to HbA1c target. <i>Journal of Diabetes and Its Complications</i> , 2013, 27, 492-500.	1.2	42
101	Efficacy and Safety of ITCA 650, a Novel Drug-Device GLP-1 Receptor Agonist, in Type 2 Diabetes Uncontrolled With Oral Antidiabetes Drugs: The FREEDOM-1 Trial. <i>Diabetes Care</i> , 2018, 41, 333-340.	4.3	41
102	A Randomized, Open-Label Comparison of Once-Weekly Insulin Icodec Titration Strategies Versus Once-Daily Insulin Glargine U100. <i>Diabetes Care</i> , 2021, 44, 1595-1603.	4.3	41
103	Safety and Efficacy of Inhaled Human Insulin (Exubera) During Discontinuation and Readministration of Therapy in Adults with Type 2 Diabetes: A 3-Year Randomized Controlled Trial. <i>Diabetes Technology and Therapeutics</i> , 2009, 11, 697-705.	2.4	36
104	Efficacy and Safety of Canagliflozin Used in Conjunction with Sulfonylurea in Patients with Type 2 Diabetes Mellitus: A Randomized, Controlled Trial. <i>Diabetes Therapy</i> , 2015, 6, 289-302.	1.2	36
105	Empagliflozin compared with glimepiride in metformin-treated patients with type 2 diabetes: 208-week data from a masked randomized controlled trial. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 2768-2777.	2.2	36
106	Colesevelam Hydrochloride to Treat Hypercholesterolemia and Improve Glycemia in Prediabetes: A Randomized, Prospective Study. <i>Endocrine Practice</i> , 2010, 16, 617-628.	1.1	35
107	Reduced risk of hypoglycemia with once-daily glargine versus twice-daily NPH and number needed to harm with NPH to demonstrate the risk of one additional hypoglycemic event in type 2 diabetes: Evidence from a long-term controlled trial. <i>Journal of Diabetes and Its Complications</i> , 2014, 28, 742-749.	1.2	35
108	FDA guidance on antihyperglycemic therapies for type 2 diabetes: One decade later. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 1073-1078.	2.2	33

#	ARTICLE	IF	CITATIONS
109	Impact of a Weekly Glucagon-Like Peptide 1 Receptor Agonist, Albiglutide, on Glycemic Control and on Reducing Prandial Insulin Use in Type 2 Diabetes Inadequately Controlled on Multiple Insulin Therapy: A Randomized Trial. <i>Diabetes Care</i> , 2020, 43, 2509-2518.	4.3	33
110	Two-Year Pulmonary Safety and Efficacy of Inhaled Human Insulin (Exubera) in Adult Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2008, 31, 1723-1728.	4.3	32
111	Initial Combination Therapy with Metformin and Colesevelam for Achievement of Glycemic and Lipid Goals Min Early Type 2 Diabetes. <i>Endocrine Practice</i> , 2010, 16, 629-640.	1.1	31
112	Basal insulin supplementation in type 2 diabetes. <i>American Journal of Medicine</i> , 2004, 116, 10-16.	0.6	30
113	Inhaled Technosphere Insulin Versus Inhaled Technosphere Placebo in Insulin-Naïve Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetes Agents. <i>Diabetes Care</i> , 2015, 38, 2274-2281.	4.3	30
114	Efficacy and safety of sotagliflozin in patients with type 2 diabetes and severe renal impairment. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 2632-2642.	2.2	30
115	Once-daily prandial lixisenatide versus once-daily rapid-acting insulin in patients with type 2 diabetes mellitus insufficiently controlled with basal insulin: analysis of data from five randomized, controlled trials. <i>Journal of Diabetes and Its Complications</i> , 2014, 28, 40-44.	1.2	28
116	Advancing Therapy in Suboptimally Controlled Basal Insulin-Treated Type 2 Diabetes: Clinical Outcomes With iGlarLixi Versus Premix BIAsp 30 in the SoliMix Randomized Controlled Trial. <i>Diabetes Care</i> , 2021, 44, 2361-2370.	4.3	28
117	Glycated Albumin at 4 Weeks Correlates with A1C Levels at 12 Weeks and Reflects Short-Term Glucose Fluctuations. <i>Endocrine Practice</i> , 2015, 21, 1195-1203.	1.1	27
118	Efficacy and tolerability of the new autoinjected suspension of exenatide once weekly versus exenatide twice daily in patients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 165-172.	2.2	27
119	Basal weekly insulins: the way of the future!. <i>Metabolism: Clinical and Experimental</i> , 2022, 126, 154924.	1.5	27
120	Diabetes and its complications: Blood glucose control vs. genetic susceptibility. <i>Diabetes/metabolism Reviews</i> , 1988, 4, 417-435.	0.2	26
121	Once-Weekly Epeglenatide Dose-Range Effects on Glycemic Control and Body Weight in Patients With Type 2 Diabetes on Metformin or Drug Naive, Referenced to Liraglutide. <i>Diabetes Care</i> , 2019, 42, 1733-1741.	4.3	26
122	Differential glycaemic control with basal insulin glargine 300 U/mL versus degludec 100 U/mL according to kidney function in type 2 diabetes: A subanalysis from the BRIGHT trial. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1369-1377.	2.2	26
123	Clinical Impact of ITCA 650, a Novel Drug-Device GLP-1 Receptor Agonist, in Uncontrolled Type 2 Diabetes and Very High Baseline HbA1c: The FREEDOM-1 HBL (High Baseline) Study. <i>Diabetes Care</i> , 2018, 41, 613-619.	4.3	25
124	Efficacy and Safety of the Glucagon Receptor Antagonist RVT-1502 in Type 2 Diabetes Uncontrolled on Metformin Monotherapy: A 12-Week Dose-Ranging Study. <i>Diabetes Care</i> , 2020, 43, 161-168.	4.3	24
125	AIR® Inhaled Insulin System: a novel insulin-delivery system for patients with diabetes. <i>Expert Review of Medical Devices</i> , 2007, 4, 683-692.	1.4	23
126	Propensity score-matched comparative analyses of simultaneously administered fixed-ratio insulin glargine 100%U and lixisenatide (iGlarLixi) vs sequential administration of insulin glargine and lixisenatide in uncontrolled type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 2821-2829.	2.2	23



#	ARTICLE	IF	CITATIONS
127	Results of a Study Comparing Glycated Albumin to Other Glycemic Indices. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 677-687.	1.8	23
128	Inhaled insulin: a novel route for insulin delivery. <i>Expert Opinion on Investigational Drugs</i> , 2002, 11, 687-691.	1.9	22
129	Missing the Point: Substituting Exenatide for Nonoptimized Insulin: Going from bad to worse!. <i>Diabetes Care</i> , 2007, 30, 2972-2973.	4.3	22
130	Impact of baseline glycated haemoglobin, diabetes duration and body mass index on clinical outcomes in the <sc>LixiLanâ€œ</sc> trial testing a titratable fixedâ€œratio combination of insulin glargine/lixisenatide (<sc>iGlarLixi</sc>) vs insulin glargine and lixisenatide monocomponents. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 1798-1804.	2.2	22
131	Empagliflozin as Add On to Basal Insulin for 78 Weeks Improves Glycemic Control with Weight Loss in Insulin-Treated Type 2 Diabetes (T2DM). <i>Canadian Journal of Diabetes</i> , 2013, 37, S32.	0.4	21
132	Fasiglifam-Induced Liver Injury in Patients With Type 2 Diabetes: Results of a Randomized Controlled Cardiovascular Outcomes Safety Trial. <i>Diabetes Care</i> , 2018, 41, 2603-2609.	4.3	19
133	Impact of baseline characteristics and betaâ€œcell function on the efficacy and safety of subcutaneous onceâ€œweekly semaglutide: A patientâ€œlevel, pooled analysis of the SUSTAIN 1â€œ5 trials. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 303-314.	2.2	19
134	Advancing therapy with <sc>iGlarLixi</sc> versus premix BIAsp 30 in basal insulinâ€œtreated type 2 diabetes: Design and baseline characteristics of the <sc>SoliMix</sc> randomized controlled trial. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 1221-1231.	2.2	19
135	Cardiovascular outcomes and safety with linagliptin, a dipeptidyl peptidaseâ€œ4 inhibitor, compared with the sulphonylurea glimepiride in older people with type 2 diabetes: A subgroup analysis of the randomized <sc>CAROLINA</sc> trial. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 569-580.	2.2	18
136	Safety and tolerability of dapagliflozin, saxagliptin and metformin in combination: <i><sc>P</sc>ostâ€œhoc</i> analysis of concomitant addâ€œon versus sequential addâ€œon to metformin and of triple versus dual therapy with metformin. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 1542-1546.	2.2	17
137	Linagliptin and cardiorenal outcomes in Asians with type 2 diabetes mellitus and established cardiovascular and/or kidney disease: subgroup analysis of the randomized CARMELINAâ€œ trial. <i>Diabetology International</i> , 2020, 11, 129-141.	0.7	17
138	Sustained 52â€œweek efficacy and safety of triple therapy with dapagliflozin plus saxagliptin versus dual therapy with sitagliptin added to metformin in patients with uncontrolled type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 883-892.	2.2	16
139	Comparing the effects of insulin glargine and thiazolidinediones on plasma lipids in type 2 diabetes: a patientâ€œlevel pooled analysis. <i>Diabetes/Metabolism Research and Reviews</i> , 2012, 28, 258-267.	1.7	15
140	Triple therapy with lowâ€œdose dapagliflozin plus saxagliptin versus dual therapy with each monocomponent, all added to metformin, in uncontrolled type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 2152-2162.	2.2	15
141	Cardiovascular and kidney outcomes of linagliptin treatment in older people with type 2 diabetes and established cardiovascular disease and/or kidney disease: A prespecified subgroup analysis of the randomized, placeboâ€œcontrolled CARMELINAâ€œ trial. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1062-1073.	2.2	14
142	Titratable fixedâ€œratio combination of basal insulin plus a glucagonâ€œlike peptideâ€œ1 receptor agonist: A novel, simplified alternative to premix insulin for type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 1445-1452.	2.2	14
143	Management of heart failure and type 2 diabetes mellitus: Maximizing complementary drug therapy. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1243-1262.	2.2	13
144	Kidney Effects of Empagliflozin in People with Type 1 Diabetes. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021, 16, 1715-1719.	2.2	13

#	ARTICLE	IF	CITATIONS
145	Comparison of Prandial AIR Inhaled Insulin Alone to Intensified Insulin Glargine Alone and to AIR Insulin Plus Intensified Insulin Glargine in Patients with Type 2 Diabetes Previously Treated with Once-Daily Insulin Glargine. <i>Diabetes Technology and Therapeutics</i> , 2009, 11, S-63-S-73.	2.4	12
146	Effect of linagliptin, a dipeptidyl peptidase-4 inhibitor, compared with the sulfonylurea glimepiride on cardiovascular outcomes in Asians with type 2 diabetes: subgroup analysis of the randomized CAROLINA <sup>®</sup> trial. <i>Diabetology International</i> , 2021, 12, 87-100.	0.7	12
147	Design and baseline characteristics of the <sc>AMPLITUDE <sup>®</sup> </sc> cardiovascular outcomes trial of efpeglenatide, a weekly glucagon-like peptide-1 receptor agonist. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 318-323.	2.2	12
148	Efficacy and safety of oral semaglutide by subgroups of patient characteristics in the <sc>PIONEER</sc> phase 3 programme. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 1338-1350.	2.2	12
149	Dapagliflozin versus saxagliptin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin. <i>Archives of Endocrinology and Metabolism</i> , 2018, 62, 424-430.	0.3	11
150	Efficacy and Safety of Once-Weekly Efpeglenatide Monotherapy Versus Placebo in Type 2 Diabetes: The AMPLITUDE-M Randomized Controlled Trial. <i>Diabetes Care</i> , 2022, 45, 1592-1600.	4.3	11
151	Exploring Patient Preferences for Adjunct-to-Insulin Therapy in Type 1 Diabetes. <i>Diabetes Care</i> , 2019, 42, 1716-1723.	4.3	10
152	Clinical Translation of Cardiovascular Outcome Trials in Type 2 Diabetes: Is There More or Is There Less Than Meets the Eye?. <i>Diabetes Care</i> , 2021, 44, 641-646.	4.3	10
153	Insulin <sup>™</sup> s Role in Diabetes Management: After 90 Years, Still Considered the Essential "Black Dress". <i>Diabetes Care</i> , 2015, 38, 2200-2203.	4.3	9
154	Impact of disease duration and Î²-cell reserve on the efficacy of switching to <sc>iGlarLixi</sc> in adults with type 2 diabetes on glucagon-like peptide-1 receptor agonist therapy: Exploratory analyses from the <sc>LixiLan <sup>®</sup> </sc> trial. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1567-1576.	2.2	9
155	Comparison of Standard (Self-Directed) Versus Intensive Patient Training for the Human Insulin Inhalation Powder (HIIP) Delivery System in Patients with Type 2 Diabetes: Efficacy, Safety, and Training Measures. <i>Diabetes Technology and Therapeutics</i> , 2007, 9, 80-88.	2.4	8
156	Clinical overview of saxagliptin for Type 2 diabetes management. <i>Expert Review of Endocrinology and Metabolism</i> , 2010, 5, 809-823.	1.2	8
157	Low-dose empagliflozin as adjunct-to-insulin therapy in type 1 diabetes: A valid modelling and simulation analysis to confirm efficacy. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 427-433.	2.2	8
158	A Lesson From 2020: Public Health Matters for Both COVID-19 and Diabetes. <i>Diabetes Care</i> , 2021, 44, 8-10.	4.3	8
159	Titration of Inhaled Human Insulin (Exubera) in a Treat-to-Target Regimen for Patients with Type 2 Diabetes. <i>Diabetes Technology and Therapeutics</i> , 2010, 12, 185-191.	2.4	7
160	Efficacy and safety of MK-1293 insulin glargine compared with originator insulin glargine (Lantus) in type 2 diabetes: A randomized, open-label clinical trial. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 2229-2237.	2.2	7
161	Glycaemic control and hypoglycaemia risk with insulin glargine 300%U/mL and insulin degludec 100%U/mL in older participants in the BRIGHT trial. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 1588-1593.	2.2	7
162	Clinical Effects of Colesevelam in Hispanic Subjects with Primary Hyperlipidemia and Prediabetes. <i>Postgraduate Medicine</i> , 2012, 124, 14-20.	0.9	6

#	ARTICLE	IF	CITATIONS
163	Similar glycaemic control and less hypoglycaemia during active titration after insulin initiation with glargine 300 units/mL and degludec 100 units/mL: A subanalysis of the BRIGHT study. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 346-354.	2.2	6
164	Real-world evidence of the effectiveness on glycaemic control of early simultaneous versus later sequential initiation of basal insulin and glucagon-like peptide-1 receptor agonists. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 2295-2304.	2.2	6
165	Effect of linagliptin versus placebo on cardiovascular and kidney outcomes in nephrotic-range proteinuria and type 2 diabetes: the CARMELINA randomized controlled trial. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 226-236.	1.4	6
166	Translating iGlarLixi Evidence for the Management of Frequent Clinical Scenarios in Type 2 Diabetes. <i>Advances in Therapy</i> , 2021, 38, 1715-1731.	1.3	6
167	Durable Effects of iGlarLixi Up to 52 Weeks in Type 2 Diabetes: The LixiLan-G Extension Study. <i>Diabetes Care</i> , 2021, 44, 774-780.	4.3	6
168	Initial Combination Therapy with Metformin plus Colesevelam in Drug-Naïve Hispanic Patients with Early Type 2 Diabetes. <i>Postgraduate Medicine</i> , 2012, 124, 7-13.	0.9	5
169	Status of Diabetes Care: "It Just Doesn't Get Any Better . . . or Does It?" <i>Diabetes Care</i> , 2014, 37, 1782-1785.	1.5	5
170	Gastrointestinal safety of incretin therapies: are we there yet?. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2016, 13, 630-632.	8.2	5
171	Efficacy and safety of MK-1293 insulin glargine compared with originator insulin glargine (Lantus) in type 1 diabetes: A randomized, open-label clinical trial. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 2220-2228.	2.2	5
172	Concomitant iGlarLixi and Sodium-Glucose Co-transporter-2 Inhibitor Therapy in Adults with Type 2 Diabetes: LixiLan-G Trial and Real-World Evidence Results. <i>Diabetes Therapy</i> , 2022, 13, 205-215.	1.2	5
173	191-OR: Similar Hypoglycemia Duration with Once-Weekly Insulin Icodec vs. Insulin Glargine U100 in Insulin Naïve or Experienced Patients with T2D. <i>Diabetes</i> , 2021, 70, .	0.3	4
174	SGLT2 Inhibition in Type 1 Diabetes with Diabetic Kidney Disease: Potential Cardiorenal Benefits Can Outweigh Preventable Risk of Diabetic Ketoacidosis. <i>Current Diabetes Reports</i> , 2022, 22, 317-332.	1.7	4
175	Is combination therapy an effective way of reaching lipid goals in Type 2 diabetes mellitus?. <i>Expert Review of Clinical Pharmacology</i> , 2012, 5, 43-54.	1.3	3
176	Cardiovascular Effects of Diabetes Drugs: Making the Dark Ages Brighter With CAROLINA. <i>Annals of Internal Medicine</i> , 2013, 158, 499.	2.0	3
177	Switching to iGlarLixi versus continuation of a daily or weekly glucagon-like peptide-1 receptor agonist (GLP-1 RA) in insufficiently controlled type 2 diabetes: A LixiLan-G trial subgroup analysis by HbA1c and GLP-1 RA use at screening. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 1331-1341.	2.2	2
178	Response to Comment on Cefalu et al. Update and Next Steps for Real-World Translation of Interventions for Type 2 Diabetes Prevention: Reflections From a <i>Diabetes Care</i> Editors' Expert Forum. <i>Diabetes Care</i> 2016;39:1186-1201. <i>Diabetes Care</i> , 2017, 40, e23-e24.	4.3	1
179	Bringing closure: towards achieving a better understanding of Israel. <i>Lancet, The</i> , 2019, 394, 559.	6.3	1
180	Differences in glycemic control between the treatment arms in cardiovascular outcome trials of type 2 diabetes medications do not explain cardiovascular benefits. <i>Journal of Pharmaceutical Policy and Practice</i> , 2021, 14, 35.	1.1	1

#	ARTICLE	IF	CITATIONS
181	Response to Comment on Rosenstock et al. Impact of a Weekly Glucagon-Like Peptide 1 Receptor Agonist, Abiglutide, on Glycemic Control and on Reducing Prandial Insulin Use in Type 2 Diabetes Inadequately Controlled on Multiple Insulin Therapy: A Randomized Trial. Diabetes Care 2020;43:2509-2518. Diabetes Care, 2021, 44, e196-e197.	4.3	1
182	Efficacy of iGlarLixi in adults with type 2 diabetes inadequately controlled ( glycated haemoglobin) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 trial. Diabetes, Obesity and Metabolism, 2022, 24, 34-41.	2.2	1
183	Management of prediabetes: setting the stage. Diabetes, Obesity and Metabolism, 2007, 9, 1-2.	2.2	0
184	Response to Comment on Rosenstock and Ferrannini. Euglycemic Diabetic Ketoacidosis: A Predictable, Detectable, and Preventable Safety Concern With SGLT2 Inhibitors. Diabetes Care 2015;38:1638-1642. Diabetes Care, 2016, 39, e139-e140.	4.3	0
185	Response to Comment on Ferrannini and Rosenstock. Clinical Translation of Cardiovascular Outcome Trials in Type 2 Diabetes: Is There More or Is There Less Than Meets the Eye? Diabetes Care 2021;44:641-646. Diabetes Care, 2021, 44, e155-e155.	4.3	0
186	Treatment of Type 2 Using Insulin. , 2008, , 69-94.		0
187	Redefining insulin therapy in type 2 diabetes mellitus. Postgraduate Medicine, 2004, 116, 21-9.	0.9	0
188	Editorial Cycles and Continuity of <i>Diabetes Care</i> . Diabetes Care, 2022, 45, 1493-1494.	4.3	0